Recent neuropathology of parkinsonian syndromes;Données récentes sur la neuropathologie des syndromes parkinsoniens

Revue Neurologique

Volumn 159, Issue 5 II, 2003, Pages

  Duyckaerts, C ^a   Verny, M ^a   Hauw, J J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CELL PROTEIN; LIGASE; PARKIN; PROTEASOME; TAU PROTEIN; UBIQUITIN;

AMYGDALOID NUCLEUS; ASTROCYTE; AUTOSOMAL RECESSIVE DISORDER; BRAIN CORTEX; BRAIN REGION; CONFERENCE PAPER; CYTOPLASM; DEMENTIA; DISEASE MARKER; DISEASE SEVERITY; ELECTRON MICROSCOPY; GENE MUTATION; GLIA CELL; HIPPOCAMPUS; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; LEWY BODY; MEYNERT BASAL NUCLEUS; MOLECULAR MECHANICS; MYELIN SHEATH; NERVE FIBER; NEURITE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OLIGODENDROGLIA; OLIVOPONTOCEREBELLAR ATROPHY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PATHOLOGICAL ANATOMY; PRESYNAPTIC NERVE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DEGRADATION; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; SYNUCLEINOPATHY;

ALPHA-SYNUCLEIN; AMYGDALA; AXONS; CEREBRAL CORTEX; CORPUS STRIATUM; CYSTEINE ENDOPEPTIDASES; HIPPOCAMPUS; HUMANS; HYPOTENSION, ORTHOSTATIC; IMMUNOHISTOCHEMISTRY; LEWY BODIES; LIGASES; MULTIENZYME COMPLEXES; MULTIPLE SYSTEM ATROPHY; MYELIN SHEATH; NERVE TISSUE PROTEINS; NEUROGLIA; OLIGODENDROGLIA; OLIVOPONTOCEREBELLAR ATROPHIES; PARKINSONIAN DISORDERS; PRESYNAPTIC TERMINALS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUPRANUCLEAR PALSY, PROGRESSIVE; SYNUCLEINS; TAU PROTEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 0038178985     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (83)

1. ABE H, YAGISHITA S, AMANO N, BISE K. (1992). Ultrastructural and immunohistochemical study of "astrocytic tangles" (ACT) in patients with progressive supranuclear palsy. Clin Neuropathol, 5: 278.
2. ADAMS RD, BOGAERT VAN L, VANDER EECKEN H. (1961). Dégénérescences nigro-striées et cérébello-nigro-striées. Psychiatria et Neurologia, 142: 219.
3. ADAMS RD, BOGAERT VAN L, VANDER EECKEN H. (1965). Striato-nigral degeneration. J Neuropathol Exp Neurol, 23: 584-608.
4. ALBERT ML, FELDMAN RG, WILLIS AL. (1974). The "subcortical dementia" of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry, 37: 121-130.
5. ARIMA K, NAKAMURA M, SUNOHARA N, et al. (1997). Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol (Berl), 93: 558-566.
6. ARIMA K, UEDA K, SUNOHARA N, et al. (1998). NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol (Berl), 96. 439-444.
7. BERGERON C, POLLANEN M. (1989). Lewy bodies in Alzheimer disease-one or two diseases? Alzheimer Dis Assoc Disord, 3: 197-204.
8. rd. (1999). Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol, 58: 359-364.
9. BOLLER F, MIZUTANI R, ROESSMANN U, GAMBETTI P. (1980). Parkinson's disease, dementia and Alzheimer's disease: clinico-pathological correlations. Ann Neurol, 1: 329-355.
10. BRAAK H, BRAAK E. (1987). Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosc Lett, 76: 124-127.
11. BRAAK H, BRAAK E, YILMAZER D, et al. (1994). Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl), 1994: 493-500.
12. CHUNG KK, ZHANG Y, LIM KL, et al. (2001). Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med, 7: 1144-1150.
13. DEMARTINO GN, SLAUGHTER CA. (1999). The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem, 274: 22123-22126.
14. DICKSON DW, LIU W, HARDY J, et al. (1999). Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol, 155: 1241-1251.
15. DICKSON DW, RUAN D, CRYSTAL H, et al. (1991). Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology, 41: 1402-1409.
16. DUFFY PE, TENNYSON VM. (1965). Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson's disease. J Neuropathol Exp Neurol, 24: 398-414.
17. DUYCKAERTS C, GASPAR P, COSTA C, BONNET AM, HAUW JJ. (1993). Dementia in Parkinson's disease. In: Advances in Neurology. Sous la direction de H. Narabayashi, T. Nagatsu, N. Yanagisawaet Y. Mizuno. New York: Raven Press, pp. 447-455.
18. EGENSPERGER R, BANCHER C, KOSEL S, JELLINGER K, MEHRAEIN P, GRAEBER MB. (1996). The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun, 224:484-486.
19. FEANY MB, DICKSON DW. (1995). Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol, 146: 1388-1396.
20. FOSTER NL, SIMA AAF, D'AMATO C, et al. (1996). Cerebral cortical pathology in progressive supranuclear palsy is correlated with severity of dementia. Neurology, 46: A363.
21. GASPAR P, GRAY F. (1984). Dementia in idiopathic Parkinson disease. A neuropathological study of 32 cases. Acta Neuropathol (Berl), 64: 43-52.
22. GEARING M, LYNN M, MIRA SS. (1999). Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups. Arch Neurol, 56: 203-208.
23. GEARING M, SCHNEIDER JA, REBECK GW, HYMAN BT, MIRRA SS. (1995). Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Neurology, 45: 1985-1990.
24. GIBB WR, LEES AJ. (1989). Prevalence of Lewy bodies in Alzheimer's disease. Ann Neurol, 26: 691-693.
25. GRAHAM JG, OPPENHEIMER DR. (1969). Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry, 32: 28-34.
26. HAKIM AM, MATHIESON G. (1979). Dementia in Parkinson disease: a neuropathologic study. Neurology, 29: 1209.
27. HANSEN L, SALMON D, GALASKO D, et al. (1990). The Lewy body variant of Alzheimer's disease:a clinical and pathologic entity. Neurology, 40: 1-8.
28. HANSEN LA, MASLIAH E, GALASKO D, TERRY RD. (1993). Plaque-only Alzheimer disease is usually the Lewy body variant and vice versa. J Neuropathol Exp Neurol, 52. 648-654.
29. HARDING AJ, BROE GA, HALLIDAY GM. (2002). Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 125: 391-403.
30. HAUW J-J, DANIEL SE, DICKSON D, et al. (1994). Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (Progressive Supranuclear Palsy). Neurology, 44: 2015-2019.
31. HAUW J-J, VERNY M, DELAÈRE P, CERVERA P, HE Y, DUYCKAERTS C. (1990). Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett, 119: 182-186.
32. HEYMAN A, FILLENBAUM GG, GEARING M, et al. (1999). Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX. Neurology, 52: 1839-1844.
33. HUGHES AJ, DANIEL SE, BLANKSON S, LEES AJ. (1993). A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol, 50: 140-148.
34. Il K, ITO H, TANAKA K, HIRANO A. (1997). Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol, 56: 125-131.
35. IKEDA K, AKIYAMA H, ARAL T, NISHIMURA T. (1998). Glial tau pathology in neurodegenerative diseases; their nature and comparison with neuronal tangles. Neurobiol Aging, 191. S85-S91.
36. IKEDA K, AKIYAMA H, HAGA C, KONDO H, ARIMA K, ODA T. (1994). Argyrophilic thread-like structure in corticobasal degeneration and supranuclear palsy. Neurosci Letters, 174: 157-159.
37. IKEDA K, AKIYAMA H, KONDO H, HAGA C, TANNO E, TOKUDA T et al. (1995). Thorn-shaped astrocytes: possibly secondarily induced taupositive glial fibrillary tangles. Acta Neuropathol (Berl), 90: 620-625.
38. INZELBERG R, CHAPMAN J, TREVES TA, ASHEROV A, KIPERVASSER S, HIL-KEWICZ O et al. (1998). Apolipoprotein E4 in Parkinson disease and dementia: new data and meta- analysis of published studies. Alzheimer Dis Assoc Disord, 12. 45-48.
39. ISEKI E, KATO M, MARUI W, UEDA K, KOSAKA K. (2001). A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies. J Neurol Sci, 185: 129-134.
40. ISHIZAWA K, LIN WL, TISEO P, HONER WG, DAVIES P, DICKSON DW. (2000). A qualitative and quantitative study of grumose degeneration in progressive supranuclear palsy. J Neuropathol Exp Neurol, 59: 513-524.
41. JENDROSKA K, KASHIWAGI M, SASSOON J, DANIEL SE. (1997). Amyloid beta-peptide and its relationship with dementia in Lewy body disease. J Neural Transm Suppl, 51:137-144.
42. KITADA T, ASAKAWA S, HATTORI N, et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392: 605-608.
43. KOMORI T. (1999). Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol, 9: 663-679.
44. KOMORI T, ARAI N, ODA M, et al. (1998). Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl), 96: 401-408.
45. KOSAKA K, YOSHIMURA M, IKEDA K, BUDKA H. (1984). Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degreea new disease? Clin Neuropathol, 3: 185-192.
46. LANTOS PL, OVENSTONE IM, JOHNSON J, CLELLAND CA, ROQUES P, ROSSOR MN. (1994). Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. Neurosci Lett, 172. 77-79.
47. LENNOX G, LOWE J, BYRNE EJ, LANDON M, MAYER RJ, GODWIN-AUSTEN RB. (1989). Diffuse Lewy body disease. Lancet, i: 323-324.
48. LEWY FH. (1923). Die Lehre vom Tonus und der Bewegung zugleich systematische Untersuchungen zur Klinik, Physiologie, Pathologie und Pathogenese der Paralysis Agitans. Berlin: Julius Springer, pp. 671.
49. LIPPA CF, FUJIWARA H, MANN DMA, et al. (1998). Lewy bodies contain altered alpha-synuclein in brains of many familiar Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol, 153: 1365-1370.
50. LIPPA CF, SCHMIDT ML, LEE VM, TROJANOWSKI JQ. (1999). Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol, 46: 353-357.
51. LOWE J, BLANCHARD A, MORRELL K, et al. (1988). Ubiquitin is common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol, 155: 9-15.
52. MAROTEAUX L, CAMPANELLI JT, SCHELLER RH. (1988). Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 8: 2804-2815.
53. MATSUSAKA H, IKEDA K, AKIYAMA H, ARAI T, INOUE M, YAGISHITA S. (1998). Astrocytic pathology in progressive supranuclear palsy: significance for neuropathological diagnosis. Acta Neuropathol (Berl), 96: 248-252.
54. MATTILA PM, RINNE JO, HELENIUS H, DICKSON DW, ROYTTA M. (2000). Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl), 100: 285-290.
55. MATTILA PM, RINNE JO, HELENIUS H, ROYTTA M. (1999). Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol (Berl), 98: 157-164.
56. MATTILA PM, ROYTTA M, TORIKKA H, DICKSON DW, RINNE JO. (1998). Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl), 95: 576-582.
57. MCKEITH IG, GALASKO D, KOSAKA K, et al. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 47: 1113-1124.
58. MCKEITH IG, PERRY EK, PERRY RH. (1999). Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology, 53: 902-905.
59. MIRRA SS. (1997). Neuropathological assessment of Alzheimer's disease: the experience of the Consortium to Establish a Registry for Alzheimer's Disease. Int Psychogeriatr, 9: 263-8; discussion 269-272.
60. NISHIMURA T, IKEDA K, AKIYAMA H, et al. (1995). Immunohistochemical investigation of tau positive structures of cerebral cortex in patients with progressive supranuclear palsy. Neurosci Lett, 201: 123-126.
61. OKAZAKI H, LIPKIN LE, ARONSON SM. (1961). Diffuse intracytoplasmic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol, 20: 237-244.
62. PAPP MI, KAHN JE, LANTOS PL. (1989). Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci, 94: 79-100.
63. PERL DP, OLANOW CW, CALNE D. (1998). Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol, 44: S19-31.
64. PERRY E, WALKER M, GRACE J, PERRY R. (1999). Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci, 22: 273-280.
65. PERRY RH, IRVING D, BLESSED G, FAIRBAIRN A, PERRY EK. (1990). Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in elderly. J Neurol Sci, 95: 119-139.
66. POLYMEROPOULOS MH, LAVEDAN C, LEROY E, et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276: 2045-2047.
67. PROBST A, LANGUI D, LAUTENSCHLAGER C, ULRICH J, BRION JP, ANDERTON BH. (1988). Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol (Berl.), 77: 61-68.
68. SERGEANT N, WATTEZ A, DELACOURTE A. (1999). Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem, 72: 1243-1249.
69. SHIMURA H, SCHLOSSMACHER MG, HATTORI N, et al. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293: 263-269.
70. SPILLANTINI MG, CROWTHER RA, JAKES R, CAIRNS NJ, LANTOS PL, GOEDERT M. (1998). Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett, 251: 205-208.
71. SPILLANTINI MG, SCHMIDT ML, LEE VMY, TROJANOWSKI JQ, JAKES R, GOEDERT M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388: 839-840.
72. STEELE JC, RICHARDSON JC, OLSZEWSKI J. (1964). Progressive supranuclear palsy; a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuclear dystonia and dementia. Arch Neurol, 10: 333-359.
73. TAKAHASHI H, OYANAGI K, TAKEDA S, HINOKUMA K, IKUTA F. (1989). Occurrence of 15-nm-wide straight tubules in neocortical neurons in progressive supranuclear palsy. Acta Neuropathol, 79: 233-239.
74. TAKAHASHI M, WEIDENHEIM KM, DICKSON DW, KSIEZAK-REDING H. (2002). Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol, 61: 33-45.
75. TOLNAY M, PROBST A. (1999). Tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol, 25: 171-187.
76. TRETIAKOFF C. Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Paris: Jouve et Cie, 1919: 124.
77. VERNY M, DUYCKAERTS C, AGID Y, HAUW JJ. (1996). The significance of cortical pathology in progressive supranuclear palsy. Brain, 119: 1123-1136.
78. VERNY M, DUYCKAERTS C, HAUW JJ. (1999). Les lésions corticales de la paralysie supranucléaire progressive (maladie de Steele-Richardson-Olszewski). Rev Neurol (Paris), 155: 15-26.
79. VERNY M, JELLINGER K, HAUW J-J, BANCHER C, LITVAN I, AGID Y. (1996). Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol (Berl), 91: 427-431.
80. WAKABAYASHI K, YOSHIMOTO M, TSUJI S, TAKAHASHI H. (1998). Alphasynuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett, 249: 180-182.
81. WOLTERS EC, BERENDSE HW. (2001). Management of psychosis in Parkinson's disease. Curr Opin Neurol, 14: 499-504.
82. YAGISHITA S, ITOH Y, AMANO N, NAKANO T, SAITOH A. (1979). Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (Berl), 48: 27-30.
83. YAMADA T, MCGEER PL, MCGEER EG. (1992). Appearance of paired nucleated, Tau positive glia in patients with progressive supranuclear palsy brain tissue. Neurosci Lett, 135: 99-102.